These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21972030)

  • 1. In silico synergism and antagonism of an anti-tumour system intervened by coupling immunotherapy and chemotherapy: a mathematical modelling approach.
    Hu WY; Zhong WR; Wang FH; Li L; Shao YZ
    Bull Math Biol; 2012 Feb; 74(2):434-52. PubMed ID: 21972030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Thoughts about the present state of tumour chemotherapy (author's transl)].
    Rieche K
    Arch Geschwulstforsch; 1976; 46(3):225-9. PubMed ID: 971043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction index and different methods for determining drug interaction in combination therapy.
    Lee JJ; Kong M; Ayers GD; Lotan R
    J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine.
    Greco WR; Park HS; Rustum YM
    Cancer Res; 1990 Sep; 50(17):5318-27. PubMed ID: 2386940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy may be delivered based on an integrated view of tumour dynamics.
    Ribba B; You B; Tod M; Girard P; Tranchand B; Trillet-Lenoir V; Freyer G
    IET Syst Biol; 2009 May; 3(3):180-90. PubMed ID: 19449978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How immunotherapy can enhance the response to other modalities and improve outcome and quality of life.
    Liu WM; Meyer B; Dalgleish AG
    J BUON; 2009 Sep; 14 Suppl 1():S103-9. PubMed ID: 19785052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour suppression by immune system through stochastic oscillations.
    Caravagna G; d'Onofrio A; Milazzo P; Barbuti R
    J Theor Biol; 2010 Aug; 265(3):336-45. PubMed ID: 20580640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study.
    Boik JC; Newman RA; Boik RJ
    Stat Med; 2008 Mar; 27(7):1040-61. PubMed ID: 17768754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fitting models for the joint action of two drugs using SAS.
    Whitehead A; Whitehead J; Todd S; Zhou Y; Smith MK
    Pharm Stat; 2008; 7(4):272-84. PubMed ID: 17979217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delay equations modeling the effects of phase-specific drugs and immunotherapy on proliferating tumor cells.
    Barbarossa MV; Kuttler C; Zinsl J
    Math Biosci Eng; 2012 Apr; 9(2):241-57. PubMed ID: 22901063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis inhibition and tumor-immune interactions with chemotherapy by a control set-valued method.
    Kassara K; Moustafid A
    Math Biosci; 2011 Jun; 231(2):135-43. PubMed ID: 21377480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mathematical formulation of additivity for antimicrobial agents.
    Boucher AN; Tam VH
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):319-25. PubMed ID: 16626903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
    Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
    Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marrying immunotherapy with chemotherapy: why say IDO?
    Muller AJ; Prendergast GC
    Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the optimal therapeutic protocols in cancer immunotherapy.
    Cappuccio A; Castiglione F; Piccoli B
    Math Biosci; 2007 Sep; 209(1):1-13. PubMed ID: 17416392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function.
    Engelhart M; Lebiedz D; Sager S
    Math Biosci; 2011 Jan; 229(1):123-34. PubMed ID: 21129386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies.
    McDougall SR; Anderson AR; Chaplain MA
    J Theor Biol; 2006 Aug; 241(3):564-89. PubMed ID: 16487543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coupled modelling of tumour angiogenesis, tumour growth and blood perfusion.
    Cai Y; Xu S; Wu J; Long Q
    J Theor Biol; 2011 Jun; 279(1):90-101. PubMed ID: 21392511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.